FINWIRES · TerminalLIVE
FINWIRES

$BHC

4 stories mentioning BHC

Every FINWIRES story that references BHC, newest first.

Mining & Metals

Bausch Health, Solta Medical Say Thermage Brand Receives China Trademark Certification

Bausch Health Companies (BHC.TO, BHC) and Solta Medical after the close Thursday said that their Thermage brand received the AAA Well-Known Trademark Certification from the China Trademark Association, a designation awarded to 217 brands across mainland China recognizing brand reputation, consumer confidence and market influence."Joining an elite group of only 217 brands nationwide, this distinction cements Thermage's position as a leader in medical aesthetics and is a powerful validation of the reliability and confidence we have established with consumers and practitioners in China," said chief executive Thomas Appio. "It underscores our commitment to innovation with the highest standards of quality and safety."engineering consulting firm shares closed up $0.03 to $7.48 on Toronto Stock Exchange.

$BHC$BHC.TO
Mining & Metals

Bausch Health Q1 Adjusted Earnings, Revenue, Advance, Beating Estimates

Bausch Health (BHC.TO) up 3.6% in after-hours New York trade, after the company on Wednesday said its first-quarter adjusted earnings and revenue both rose, beating estimates.Adjusted net income, which excludes most one-time items, rose to US$296 million, or US$0.78 per share, from US$220 million, or US$0.59, in the prior-year period. Analysts polled by FactSet had expected US$0.67 per share.Consolidated revenue jumped 12% to US$2.52 billion, beating the US$2.4 billion FactSet forecast.Bausch Health maintained its fiscal 2026 revenue guidance of US$5.25 billion to US$5.4 billion and adjusted EBITDA of US$2.875 billion to US$2.95 billion, both excluding Bausch + Lomb."Our first quarter performance marks twelve consecutive periods of year-over-year growth in revenue, adjusted EBITDA for Bausch Health excluding Bausch + Lomb, reflecting strategic execution and disciplined accountability across our organization. We continue to invest in our pipeline, including the advancement of larsucosterol to treat alcohol-associated hepatitis, while pursuing business development opportunities aligned with our strategic priorities. With this momentum, we reaffirm our full-year 2026 outlook and remain focused on driving sustainable performance and shareholder value," said chief executive Thomas Appio.Bausch Health shares were last seen up US$0.20, to US$5.79 in after-hours trade. They closed down $0.11 to $7.66 on the Toronto Stock Exchange.

$BHC$BHC.TO
Mining & Metals

RBC Capital Trims Bausch Health Companies Price Target to US$9.00; Maintains Sector Perform

RBC Capital Market trimmed its price target on the shares of Bausch Health Companies (BHC.TO, BHC) by US$1.00 to US$9.00, with a sector-perform rating ahead of the company's first-quarter earnings.Analyst Douglas Miehm is forecasting revenue of US$2.43 billion, slightly above consensus forecast of US$2.41 billion.The lowered price target of US$9.00 reflects revised estimates and lowered total prescriptions for key drugs, Miehm says, noting that total prescriptions for Xifaxan 550mg formulation declined 6.2% y/y in the first quarter, following a 1.1% y/y decline in the fourth quarter. However, he anticipates volume losses will be partially offset by improved net pricing.Key areas of focus for the earnings include updates on the Xifaxan patent litigation, management's strategic vision for monetizing the Bausch & Lomb (BLCO.TO) asset, and the return to growth at Solta following a depressed fourth quarter, he adds.Bausch Health reports its first-quarter earnings after market close on April 29.Price: $7.81, Change: $+0.12, Percent Change: +1.56%

$BHC$BHC.TO
Wire

Bausch Health's Q1 Total Prescriptions Hurt by Exit From Federal Drug Pricing Programs, RBC Says

Bausch Health's (BHC) total prescriptions in Q1 were likely to be negatively impacted by the company's exit from the US federal drug pricing programs in October 2025, RBC Capital Markets said in a Monday note.Prescriptions of the 550-miiligram formulation of the company's top-selling Xifaxan, used to treat gastrointestinal conditions, dropped 6.2% in Q1 year over year after a 1.1% decline in Q4, RBC analysts said. They expect volume losses to be partially offset by improved net pricing and revised their Xifaxan revenue forecast to $480 million from $487 million.The company's Q1 revenue is projected at $2.43 billion, compared with the consensus of $2.41 billion, according to the note.Investors are likely to focus on the ongoing litigation involving Xifaxan's patent; Bausch Health's plan to monetize the Bausch + Lomb (BLCO) asset after the genericization of Xifaxan, expected in January 2028; and a growth rebound for its Solta Medical aesthetics business, the analysts said.Bausch Health is expected to report Q1 financial results after market-close on Wednesday.RBC maintained the company's stock rating at sector-perform and lowered the price target to $9 from $10.Price: $5.70, Change: $+0.07, Percent Change: +1.15%

$BHC$BLCO